All News

WASHINGTON--Joint ventures between community hospitals and university departments of oncology can offer significant benefits to both, but not unless all parties involved understand one another and formulate a well thought out program.

A study currently underway at the Medical College of Wisconsin is looking at why farmers do or do not follow safe-use guidelines when applying pesticides and is measuring their levels of pesticide exposure

WASHINGTON--Despite increasing complaints from physicians and patients, don't look for Congress to take any action in 1996 to remedy the problems that have evolved with the growth of managed care, a key Senate aide said at the national meeting of the Association of Community Cancer Centers (ACCC).

MONTREAL--A new instrument for measuring pain intensity--the visual analogue thermometer (VAT)--developed to overcome some of the disadvantages of the conventional visual analogue scale (VAS)--has proved "valid, accurate, and clinically useful" in two studies, say Manon Choinière, PhD, of the Burn Centre, Hotel-Dieu Hospital of Montreal and the University of Montreal, and Rhonda Amsel, MSc, of the Department of Psychology, McGill University.

Physicians today are facing more ethical dilemmas as patient decisions are being based less on beneficence and more on business models of success, says Sister Patricia Talone, ethics consultant, Mercy Health Corporation of Southeastern

BETHESDA, Md--Newly available from the NIH/NCI (NIH Publication 96-4104, April 1996) is a SEER monograph entitled Racial/Ethnic Patterns of Cancer in the United States, 1988-1992.

In the United States, the implementation of antibody testing in 1985 of all donated blood for human immunodeficiency virus type 1 (HIV-1) resulted in a substantial decrease in the transmission of HIV through blood transfusions. To further decrease

PHILADELPHIA--Forging ahead with change was the theme of the second annual meeting of the Association of Cancer Executives (ACE). And for most of the speakers, change meant adapting to the new reality of managed care and hospital mergers.

PHILADELPHIA--During his tenure at Brigham and Women's Hospital, Lawrence Shulman, MD, has been involved in two hospital mergers. The first, with Massachusetts General Hospital, was done in secrecy, while the latest, with the Dana-Farber Cancer Institute, has been an open process.

This timely and informative review describes the components of a cost-effectiveness analysis and provides useful commentary on various ways to measure them. It may be helpful, however, to take a step back and compare cost-effectiveness analysis to the other basic approaches to economic analysis.

WASHINGTON--In an experiment that may blur the line between therapeutic and preventive medications, researchers from the University of Wisconsin, Madison, plan to move a novel new compound to phase II testing in advanced cancer patients.

WASHINGTON--Employers, who first embraced managed care as a way to lower health care costs, are now joining together in buying coalitions to extract even greater price reductions from organizations such as HMOs from whom they purchase health care insurance for their employees.

It used to take Mike Natishak, Sr., his wife Mary Alice, and their 9-year-old son Mike Jr., 6 hours to make the weekly drive from their home in Apalachin, NY, to Boston Children's Hospital. They had to stay over at a hotel to be at the hospital the next morning. So in addition to travel expenses, the Natishaks each lost 2 days of work.

ASCO--Both forms of recombinant human platelet growth factor currently under study have been shown to enhance platelet recovery after myelosup-pressive chemotherapy without serious side effects. The first four clinical trials of the two products--pegylated megakaryocyte growth and development factor (MGDF, Amgen), which is linked to polyethylene glycol to improve its stability and half-life; and thrombopoietin (rhTPO, Genentech)--were presented at an ASCO scientific symposium.

NeXstar Pharmaceuticals made four DaunoXome-related presentations at the 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy in Amsterdam, The Netherlands. Parkash S. Gill, MD, associate professor medicine and pathology at the

Rockville, Md --GenVec has begun a phase I study of its in vivo gene-based product, AdgvCD. 10, in 18 patients with liver metastases of colectoral cancer . An advenovirus vector modified to carry the cytosine deaminase gene will be administered directly into the hepatic tumor. The gene expresses an enzyme that converts 5-fluorocytosine,an oral anti-fungal agent , into the potent anticancer agent 5-fluorouracil.. The conversion occurs only at the site of gene expression, the company said.

PHILADELPHIA--The strategy of the Washington Hospital Center (WHC) cancer program for surviving managed care has been to enthusiastically embrace change, said Kenneth Samet, president of WHC, at the annual meeting of the Association of Cancer Executives (ACE).

BETHESDA, Md--At the 98th Meeting of the National Cancer Advisory Board (NCAB), Dr. Richard Klausner, director of the National Cancer Institute (NCI), congratulated everyone at the NCI on weathering the first year of structural changes under his new leadership.

PHILADELPHIA--When practice guidelines or pathways take financial considerations into account, they may be termed clinical financial pathways (CFPs). This technique was developed by Kent Giles, MPPM, vice president of development at PhyMatrix, a physician management company headquartered in West Palm Beach, Fla, and is currently being utilized by PhyMatrix to reduce unnecessary medical costs.

NEW YORK--All physicians, regardless of their specialty, must be prepared to treat HIV-infected patients, according to an expert from the Centers for Disease Control and Prevention. Although fears of nosocomial transmission of the virus are not unwarranted, much can be done to avoid it.

his excellent review analyzes ophthalmologic complications following high-dose irradiation of the orbit and surrounding structures as a necessary adjunct to the treatment of patients with carcinomas of the head and neck region. It confirms the critical importance of dose-fraction size in the production of radiation complications, especially in nerve tissue.

The failure to contain health-care costs and curtail growth is a growing national economic concern and public policy issue. The marketplace is rapidly changing how health care is paid for by moving from fee-for-service mechanisms to prospective payment, diagnosis-related groups, and increasing exclusion of some treatment(s).

Parsons and colleagues present an excellent summary of their clinical experience with ocular complications of radiotherapy for primary periocular malignancies, together with a retrospective review of the literature on this subject. The authors emphasize the roles of both total dose and dose-per-fraction in radiation-associated eye complications.

pplication of the techniques of flow cytometry and image analysis to quantitation of DNA and estimation of events in the cell cycle in human tumors has achieved considerable popularity as a laboratory procedure but so far has failed to be of practical clinical value. As brilliantly summarized by Dr. Ross, retrospective studies have repeatedly shown abnormal DNA values to be of prognostic significance in several organ systems, among them, tumors of the urothelium [1] and prostate [2] and, perhaps to a lesser extent, mammary carcinomas [3].

This comprehensive report summarizes the current management of primary liver cancer and of metastatic colorectal cancer in the liver. Numerous tests to help define the location and stage of disease have been evaluated. It now appears that spiral CT with arterial portography is superior to other nonoperative methods in evaluating liver tumors. Immunoscintography using monoclonal antibodies is currently under development and appears to be of potential great value. Subclinical, micrometastatic disease is the bane of all efforts at surgical control of cancer. An ability to detect this would have far-reaching consequences. Complete evaluation of patients with these diseases must include a medical evaluation, including liver function tests and a chest CT. Particular attention must also be paid to cardiac, pulmonary, and renal function.

That nucleic acids can be measured spectrophotometrically in intact, fixed, or viable single cells was demonstrated in a series of publications by Caspersson in the 1930s and '40s, culminating in his now classic monograph [1]. In that paper, Caspersson demonstrated an increase in nucleic acid content in proliferating vs resting cells and malignant vs benign cells. However, although his measurements of ultraviolet absorption were specific for nucleic acids, the absorption maximums for DNA and RNA were too close to be distinguished. Probably, he was measuring differences in RNA, which are more striking than differences in DNA.

The article by Dr. Ross provides an overview of the current status of the medical literature regarding the role of DNA ploidy and cell cycle analysis in cancer diagnosis and patient prognosis. The scope of the article is quite broad, covering virtually every organ system and, as such, provides only a brief summary of the data in each diagnostic category. From these data, there is general agreement about the value of detection of aneuploidy in tumor specimens but a lack of consensus about the importance of cell proliferation analyses, such as S-phase fraction (SPF) measurements. This conclusion reflects the inherent variability in the two determinations. Detection of aneuploidy by analytic cytometry is reliable; it is accurate and depends upon the specimen (frozen vs formaldehyde- fixed, presence of necrosis, cellularity) as well as the quality of specimen preparation. Thus, DNA ploidy analysis can easily be standardized, minimizing intralaboratory variation. Cell cycle analysis, however, is more complex and as yet is not standardized.

Dr. Sardi and colleagues lay out, in a clear and concise fashion, current alternatives for the management of primary and metastatic liver tumors. Their emphasis on "high-value" treatments is crucial. In this group of patients, unnecessary treatments not only are costly in terms of dollars but also reduce the quality of the short life remaining in patients with unresectable disease.

Primary and metastatic liver tumors continue to be a significant health problem in the United States. Hepatic resection or, in selected cases, transplantation are the only curative therapies for patients with resectable

Historically, new therapeutic strategies for cancer have been evaluated on the basis of safety and clinical efficacy. However, the current national emphasis on efficiency of resource allocation has led to the inclusion of economic assessments in oncology studies. Economic assessments measure patients' health status and resource consumption associated with a therapeutic strategy, and combine these in a cost-effectiveness analysis. Study design can include prospective analysis of clinical trials, retrospective analysis of a clinical trial or administrative databases, or a decision analytic model. Economic analysis is being used increasingly in oncology and will continue to provide meaningful data to assist clinicians in determining the optimal treatment strategies for cancer patients and to help inform health policy decision-makers about the importance of specific cancer therapeutic strategies. [ONCOLOGY 9(6):523-538, 1995]